This morning we watched Viatris drop -1.7% to a price of $11.8 per share. The large-cap Drug Manufacturing company is now trading -18.13% below its average target price of $14.42. Analysts have set target prices ranging from $9 to $35 per share for Viatris, and have given the stock an average rating of hold.
Viatris's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.3%. The stock's short ratio is 2.26. The company's insiders own 0.21% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 75.7%. In conclusion, we believe there is mixed market sentiment regarding Viatris.
Institutions Invested in Viatris
| Holder | Shares | Date Reported | Percentage | Value |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 145,344,236 | 2022-06-29 | 12% | $1,521,754,150 |
| Blackrock Inc. | 93,510,570 | 2022-06-29 | 8% | $979,055,667 |
| State Street Corporation | 58,084,474 | 2022-06-29 | 5% | $608,144,442 |
| Davis Selected Advisers, LP | 55,466,147 | 2022-06-29 | 5% | $580,730,559 |
| Wellington Management Group, LLP | 55,233,099 | 2022-06-29 | 5% | $578,290,546 |
| Geode Capital Management, LLC | 24,881,035 | 2022-06-29 | 2% | $260,504,436 |
| Camber Capital Management LP | 23,000,000 | 2022-06-29 | 2% | $240,810,000 |
| Deerfield Management Company, L.P. (Series C) | 20,673,700 | 2022-06-29 | 2% | $216,453,639 |
| Laurion Capital Management, LP | 18,421,408 | 2022-06-29 | 2% | $192,872,141 |
| Schroder Investment Management Group | 16,529,051 | 2022-06-29 | 1% | $173,059,163 |
